NICE rejects Sanofi’s Duxipent for Asthma

The UK’s National Institute for Health and Care Excellence (NICE) turned down Sanofi’s Duxipent (dupilumab) for treating severe asthma with type 2 inflammation that is inadequately controlled in patients aged 12 years and older.

NICE found that clinical trials showed dupilumab with standard treatment reduces exacerbations and the use of oral corticosteroids compared to placebo, but there are no trials directly comparing dupilumab with other treatments like mepolizumab, reslizumab or benralizumab.

NICE also said that the cost-effectiveness estimates for dupilumab are higher than what it considers an acceptable use of NHS resources.